
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Fatima Karzai, MD, discusses clinical trial diversity, equity, and inclusion and the path forward.
Fatima Karzai, MD, discusses clinical trial diversity, equity, and inclusion and the path forward.






